Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: The DOPPS study

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 1, 2015, Pages 98-109

  Tentori, Francesca ^a,j   Wang, Mia ^a   Bieber, Brian A ^a   Karaboyas, Angelo ^a   Li, Yun ^a,b   Jacobson, Stefan H ^c   Andreucci, Vittorio E ^d   Fukagawa, Masafumi ^e   Frimat, Luc ^f,g   Mendelssohn, David C ^h   Port, Friedrich K ^a   Pisoni, Ronald L ^a   Robinson, Bruce M ^a,i  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c Sweden Karolinska Institutet Department of Clinical Sciences Danderyd Hospital Stressrehab FoU Danderyd   (Sweden)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f INSERM   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h HUMBER RIVER REGIONAL HOSPITAL   (Canada)

ⁱ UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; VITAMIN D DERIVATIVE; BIOLOGICAL MARKER; CALCIMIMETIC AGENT; NAPHTHALENE DERIVATIVE; PARATHYROID HORMONE; PTH PROTEIN, HUMAN; VITAMIN D;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY ANALYSIS; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; COMPLICATION; DIET SUPPLEMENTATION; HYPERPARATHYROIDISM, SECONDARY; MULTICENTER STUDY; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; TRENDS; UPREGULATION;

ADULT; AGED; BIOMARKERS; CALCIMIMETIC AGENTS; CINACALCET HYDROCHLORIDE; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PARATHYROIDECTOMY; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION; VITAMIN D;

EID: 84923872834     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12941213     Document Type: Article

References (46)

1. United States Renal Data System: 2012 United States Renal Data System Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, 2012.
2. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478–1483, 2000.
3. de Francisco AM, Ellis HA, Owen JP, Cassidy MJ, Farndon JR, Ward MK, Kerr DN: Parathyroidectomy in chronic renal failure. Q J Med 55: 289–315, 1985.
4. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31–38, 2007.
5. Chertow GM, Plone M, Dillon MA, Burke SK, Slatopolsky E: Hyperparathyroidism and dialysis vintage. Clin Nephrol 54: 295–300, 2000.
6. Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F: Parathyroidectomy in patients on renal replacement therapy: An epidemiologic study. J Am Soc Nephrol 12: 1242–1248, 2001.
7. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208–2218, 2004.
8. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16: 1788–1793, 2005.
9. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of alteredmineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179–1187, 2005.
10. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771–780, 2006.
11. Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Fukuhara S, Akizawa T, Saito A, Asano Y, Kurokawa K, Pisoni RL, Port FK: Association of mineral metabolismfactorswith all-cause and cardiovascular mortality in hemodialysis patients: The Japan dialysis outcomes and practice patterns study. Hemodial Int 11: 340–348, 2007.
12. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519–530, 2008.
13. Lacson E Jr., Wang W, Hakim RM, Teng M, Lazarus JM: Associates of mortality and hospitalization in hemodialysis: Potentially actionable laboratory variables and vascular access. Am J Kidney Dis 53: 79–90, 2009.
14. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, Fouqueray B, Wheeler DC; ARO Investigators: Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 26: 1948–1955, 2011.
15. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, Strippoli GF: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. JAMA 305: 1119–1127, 2011.
16. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone-Disorder (CKD-MBD). Kidney Int Suppl 113: S1–S130, 2009.
17. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S: KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKDMBD). Am J Kidney Dis 55: 773–799, 2010.
18. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1–S201, 2003.
19. Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA: The Dialysis Outcomes and Practice Patterns Study (DOPPS): Design, data elements, and methodology. Am J Kidney Dis 44[Suppl 2]: 7–15, 2004.
20. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, Maroni BL, Wolfe RA, Held PJ: The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study. Kidney Int 57: S74–S81, 2000.
21. Angrist JD, Imbens GW, Rubin DB: Identification of causal effects using instrumental variables. J Am Stat Assoc 91: 444–455, 1996.
22. Wooldridge JM. Introductory Econometrics: A Modern Approach, Southwestern College Publishers, Mason, OH, 2008.
23. Terza JV, Basu A, Rathouz PJ: Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. J Health Econ 27: 531–543, 2008.
24. Mendelssohn DC, Pisoni RL, Arrington CJ, Yeates KE, Leblanc M, Deziel C, Akiba T, Krishnan M, Fukuhara S, Lameire N, Port FK, Wolfe RA: A practice-related risk score (PRS): A DOPPS-derived aggregate quality index for haemodialysis facilities. Nephrol Dial Transplant 23: 3227–3233, 2008.
25. Raghunathan TE, Solenberger PW, Van Hoewyk J: IVEware: Imputation and Variance Estimation Software, Survey Methodology Program, Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, 2002.
26. Cameron AC, Trivedi PK: Microeconomics Methods and Applications, New York, Cambridge University Press, 2005, p 103.
27. Akizawa T, Kido R, Fukagawa M, Onishi Y, Yamaguchi T, Hasegawa T, Fukuhara S, Kurokawa K: Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: Associations with changing practice patterns. Clin J Am Soc Nephrol 6: 2280–2288, 2011.
28. Li S, Chen YW, Peng Y, Foley RN, St Peter WL: Trends in parathyroidectomy rates in US hemodialysis patients from 1992 to 2007. Am J Kidney Dis 57: 602–611, 2011.
29. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489– 495, 2005.
30. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525, 2004.
31. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 16: 800–807, 2005.
32. St Peter WL, Li Q, Liu J, Persky M, Nieman K, Arko C, Block GA: Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 4: 354–360, 2009.
33. Fukagawa M, Fukuma S, Onishi Y, Yamaguchi T, Hasegawa T, Akizawa T, Kurokawa K, Fukuhara S: Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: Results from the MBD-5D study. Clin J Am Soc Nephrol 7: 1473–1480, 2012.
34. Perkovic V, Neal B: Trials in kidney disease—time to EVOLVE. N Engl J Med 367: 2541–2542, 2012.
35. Guideline Working Group, Japanese Society for Dialysis Therapy: Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12: 514–525, 2008.
36. Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori M, Ashida A, Iseki K, Shigematsu T, Tsukamoto Y, Tsubakihara Y, Tomo T, Hirakata H, Akizawa T; CKD-MBD Guideline Working Group; Japanese Society for Dialysis Therapy: Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 17: 247–288, 2013.
37. Li J, Molnar MZ, Zaritsky JJ, Sim JJ, Streja E, Kovesdy CP, Salusky I, Kalantar-Zadeh K: Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrol Dial Transplant 28: 1516–1525, 2013.
38. Avram MM, Mittman N, Myint MM, Fein P: Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 38: 1351–1357, 2001.
39. Drechsler C, Krane V, Grootendorst DC, Ritz E, Winkler K, März W, Dekker F, Wanner C; German Diabetes and Dialysis Study Investigators: The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant 24: 3151–3157, 2009.
40. London GM, Marchais SJ, Guérin AP, Boutouyrie P, Métivier F, de Vernejoul MC: Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 19: 1827–1835, 2008.
41. Block GA, Kilpatrick RD, Lowe KA, Wang W, Danese MD: CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol 8: 2132–2140, 2013.
42. Ledebo I, Lameire N, Charra B, Locatelli F, Kooistra M, Kessler M, Jacobs C: Improving the outcome of dialysis—opinion vs scientific evidence. Report on the Dialysis Opinion Symposium at the ERA-EDTA Congress, 6 September 1999, Madrid. Nephrol Dial Transplant 15: 1310–1316, 2000.
43. Mactier R, Davies S, Dudley C, Harden P, Jones C, Kanagasundaram S, Lewington A, Richardson D, Taal M, Andrews P, Baker R, Breen C, Duncan N, Farrington K, Fluck R, Geddes C, Goldsmith D, Hoenich N, Holt S, Jardine A, Jenkins S, Kumwenda M, Lindley E, Macgregor M, Mikhail A, Sharples E, Shrestha B, Shrivastava R, Steddon S, Warwick G, Wilkie M, Woodrow G, Wright M: Summary of the 5th edition of the Renal Association Clinical Practice Guidelines (2009-2012). Nephron Clin Pract 118[Suppl 1]: c27–c70, 2011.
44. Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, Culleton BF; Canadian Society of Nephrology Committee for Clinical Practice Guidelines: Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 17[Suppl 1]: S1–S27, 2006.
45. McMahon LP, MacGinley R; KHA-CARI: KHA-CARI guideline: Biochemical and haematological targets: Haemoglobin concentrations in patients using erythropoietin-stimulating agents. Nephrology (Carlton) 17: 17–19, 2012.
46. Elder G, Faull R, Branley P, Hawley C; Caring for Australasians with Renal Impairment (CARI): The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton) 11[Suppl 1]: S230–S261, 2006.